Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MiniMed Group, Inc.MMED · Entity 3758 | Director | October 09, 2026 | October 13, 2026 |
| Orexigen Therapeutics, Inc.OREX · Entity 157016 | Director | July 14, 2017 | July 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MiniMed Group, Inc.
Report date October 09, 2026 · Filed October 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,795 |
Reported balance
After 2026-10-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-09 · Grant · Acquired 11,795 · Balance 11,795 F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date. F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date.
F2: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs.
Orexigen Therapeutics, Inc.
Report date July 14, 2017 · Filed July 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.88 · Expires 2027-07-13 | Direct | 5,000 |
Reported balance
After 2017-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-14 · Grant · Acquired 5,000 · Balance 5,000 F1: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Zeltiq Aesthetics Inc
Report date April 28, 2017 · Filed April 28, 2017
Section 16 reporting ended · disclosed 2017-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-04-28 transaction · row 1
1 source rowRow 1 · 2017-04-28 · Other · Disposed 16,132 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2: Pursuant to the terms of the Merger Agreement, out of the total of 16,132 shares held by the Reporting Person, (i) 8,477 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes, and (ii) 7,655 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger").
F2: Pursuant to the terms of the Merger Agreement, out of the total of 16,132 shares held by the Reporting Person, (i) 8,477 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes, and (ii) 7,655 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 09, 2026 Filed Oct 13, 2026 22:10 UTC | MiniMed Group, Inc. MMED · Entity 3758 | GrantCommon Stock | 11,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001532133-26-000004 · wk-form4_1791929430.xml · nonDerivative · entry 1 Endicott David J. · CIK 0001532133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,795 F1 · shares: Represents the grant of restricted stock units ("RSUs") pursuant to the 2026 MiniMed Group, Inc. Long Term Incentive Plan that vest on the one-year anniversary of the grant date. F2 · balance_after: Includes shares of common stock to be issued in connection with the vesting of one or more RSUs. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 19:30 UTC | Orexigen Therapeutics, Inc. OREX · Entity 157016 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001209191-17-045598 · doc4.xml · derivative · entry 1 Endicott David J. · CIK 0001532133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 13:18 UTC | Zeltiq Aesthetics Inc ZLTQ · Entity 176636 | OtherCommon Stock | 16,132 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-028602 · doc4.xml · nonDerivative · entry 1 Endicott David J. · CIK 0001532133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2 · kind: Pursuant to the terms of the Merger Agreement, out of the total of 16,132 shares held by the Reporting Person, (i) 8,477 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes, and (ii) 7,655 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 13, 2017, by and among Allergan Holdco US, Inc., a wholly owned subsidiary of Allergan plc ("Allergan"), Blizzard Merger Sub, Inc. ("Merger Sub"), and the Issuer (the "Merger Agreement"), as approved by the board of directors of the Issuer, whereby Merger Sub merged with and into the Issuer, with the Issuer continuing on as the surviving corporation (the "Merger"). F2 · price: Pursuant to the terms of the Merger Agreement, out of the total of 16,132 shares held by the Reporting Person, (i) 8,477 shares were canceled and converted into the right to receive $56.50 per share in cash, without interest and subject to any applicable withholding of taxes, and (ii) 7,655 shares, representing unvested restricted stock units, were converted into a corresponding award of restricted stock units with respect to ordinary shares of Allergan, on the same terms and conditions as were applicable under such restricted stock units, as adjusted based on an exchange ratio. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.